Treatment With PTH After Sternotomy in Cardiac Surgery Patients (PAATH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01466829|
Recruitment Status : Completed
First Posted : November 8, 2011
Last Update Posted : June 2, 2014
|Condition or disease||Intervention/treatment||Phase|
|Disruption or Dehiscence of Closure of Sternum or Sternotomy||Drug: Parathyroid hormone Drug: Placebo||Phase 3|
Heart surgery is most commonly performed through a central division of the sternum, a sternotomy. This procedure provides full overview of the thoracic cavity and access to the organs within. At the department of Cardiothoracic & Vascular Surgery at Skejby Hospital alone, over 1000 sternotomies are performed each year. When closing the sternum, the normal procedure is to use steel wires to hold the two sternal halves together. The patient receives no additional medical treatment to improve bone healing. Following surgery, sufficient healing of the sternum is important to prevent complications and to ensure a high level of life-quality for the patient. It has been shown that forces, equally to those produced during a normal cough, can displace the wire-fixated sternum by more than 2 mm. Reduced stability of the sternum has a negative impact on the healing process and increases the risk of infections. Another known complication to sternotomy is pseudoarthrosis (nonunion), which is caused by insufficient healing of the sternum and may result in instability, chronic pain and reduced quality of life. These complications result in prolonged admittance time, increased mortality and morbidity and from a financial point of view, increased treatment-costs for each patient.
Parathyroid hormone (PTH) is a well known anabolic drug and has been used to treat osteoporosis in post-menopausal women with great effect. A continuous high level of PTH decreases bone density and induces hypercalcemia, but if given once daily PTH has an anabolic effect on bone. It is being investigated if it is possible to use PTH in the treatment of other conditions, for example in the treatment of bone fractures.
Several studies, both clinical and experimental, show that PTH advances healing time and increases the quality of newly formed bone. It has also been shown to enable healing in sternal nonunion in one case-study. A recent human study of 102 osteoporotic women, with fractures of their radial bone, showed that daily injection with 20µg of the PTH-analog PTH1-34 (Teriparatide) reduces the fracture healing time. The effect of PTH on bone healing in sternum after a sternotomy has not previously been investigated.
In this study, we aim to investigate the effect of PTH on sternal healing in a clinical setup.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Clinical Effects of Parathyroid Hormone as Adjuvant Therapy for Bone Healing After Sternotomy.|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||March 2014|
Placebo Comparator: Control
Control patients treated with placebo.
Placebo; saline injection.
Active Comparator: Intervention
Daily injection with Parathyroid hormone
Drug: Parathyroid hormone
100 microgram daily. S.c
Other Name: Preotact®
- Computer Tomography [ Time Frame: 6 weeks (± 1 week), 3 months (± 2 weeks) and 6 months (± 2 weeks) ]Change in density of the fracture in the sternum at different time frames compared with baseline at 6 weeks.
- Questionnaires [ Time Frame: Baseline, 6 weeks (± 1 week), 3 months (± 2 weeks), 6 months (± 2 weeks) ]Change of quality of life at different time frames compared with baseline.
- Journal parameters [ Time Frame: Baseline, 6 weeks (± 1 week), 3 months (± 2 weeks), 6 months (± 2 weeks) ]Admission time, blood tests, cross-clamp time, bypass time, time of mechanical ventilation, duration of surgery, pacingwires, type of operation, treatment with bisphosphonates, treatment with steroids, COLD, use of analgetics.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01466829
|Dept. of Cardiothoracic & Vascular Surgery, AArhus University Hospital, Skejby|
|Aarhus N, Denmark, 8200|
|Principal Investigator:||Per Nielsen, MD||Dept. of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Skejby|